Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00435513
Status:
COMPLETED
Last Update Posted:
2015-05-05
First Post:
2007-02-14
Brief Title:
A Common Polymorphism of the SRD5A2 Gene is Not Associated With Male-to-Female and Female-to-Male Transsexualism
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Association Study of a SRD5A2 SNP and Transsexualism
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Genetic variations ie polymorphisms may be associated with gender dysphoria eg transsexualism This study aims to identify such variations
Detailed Description:
Context Early developmental exposure of the brain to sex steroids may play a role in the etiology of transsexualism
Objective To assess the association between transsexualism and allele and genotype frequencies of the steroid 5-alpha reductase SRD5A2 Val89Leu polymorphism
Design and Patients We performed a case-control study of 100 male-to-female MtF transsexuals 47 female-to-male FtM transsexuals 755 male controls and 915 female controls DNA was extracted from buccal swabs and genotypes were determined by polymerase chain reaction
Results SRD5A2 Val89Leu allele frequencies SRD5A2 V 137200 69 and SRD5A2 L 63200 31 vs SRD5A2 V 10651510 71 and SRD5A2 L 4451510 29 respectively p06 Odds Ratio OR 110 95 Confidence Interval CI 076-158 and genotype distributions SRD5A2 VVVL 92100 92 and LL 8100 8 vs SRD5A2 VVVL 683755 91 and LL 72755 9 respectively p07 OR 082 95 CI 024-284 were not significantly different between MtF transsexuals and male controls SRD5A2 Val89Leu allele frequencies SRD5A2 V 7094 74 and SRD5A2 L 2494 26 vs SRD5A2 V 12531830 69 and SRD5A2 L 5731830 31 respectively p03 OR 075 95 CI 045-126 and genotype distributions SRD5A2 VVVL 4447 93 and LL 347 7 vs SRD5A2 VVVL 823915 90 and LL 92915 10 respectively p06 OR 061 95 CI 011-332 were also not significantly different between FtM transsexuals and female controls Of note there was no gender-specific genotype distribution among controls
Conclusions The SRD5A2 Val89Leu polymorphism is not associated with transsexualism and is no candidate gene of this condition
Objective To assess the association between transsexualism and allele and genotype frequencies of the steroid 5-alpha reductase SRD5A2 Val89Leu polymorphism
Design and Patients We performed a case-control study of 100 male-to-female MtF transsexuals 47 female-to-male FtM transsexuals 755 male controls and 915 female controls DNA was extracted from buccal swabs and genotypes were determined by polymerase chain reaction
Results SRD5A2 Val89Leu allele frequencies SRD5A2 V 137200 69 and SRD5A2 L 63200 31 vs SRD5A2 V 10651510 71 and SRD5A2 L 4451510 29 respectively p06 Odds Ratio OR 110 95 Confidence Interval CI 076-158 and genotype distributions SRD5A2 VVVL 92100 92 and LL 8100 8 vs SRD5A2 VVVL 683755 91 and LL 72755 9 respectively p07 OR 082 95 CI 024-284 were not significantly different between MtF transsexuals and male controls SRD5A2 Val89Leu allele frequencies SRD5A2 V 7094 74 and SRD5A2 L 2494 26 vs SRD5A2 V 12531830 69 and SRD5A2 L 5731830 31 respectively p03 OR 075 95 CI 045-126 and genotype distributions SRD5A2 VVVL 4447 93 and LL 347 7 vs SRD5A2 VVVL 823915 90 and LL 92915 10 respectively p06 OR 061 95 CI 011-332 were also not significantly different between FtM transsexuals and female controls Of note there was no gender-specific genotype distribution among controls
Conclusions The SRD5A2 Val89Leu polymorphism is not associated with transsexualism and is no candidate gene of this condition
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None